Search results
Results from the WOW.Com Content Network
Chondrosarcoma is a bone sarcoma, a primary cancer composed of cells derived from transformed cells that produce cartilage. [1] A chondrosarcoma is a member of a category of tumors of bone and soft tissue known as sarcomas. About 30% of bone sarcomas are chondrosarcomas. [2] It is resistant to chemotherapy and radiotherapy. Unlike other primary ...
EMC was firstly described in 1953 by Stout et al. when they discussed the different species of extraskeletal chondrosarcoma, [2] but EMC concept was firstly proposed in 1972 by Enzinger et al. [3] Brody thought that this was a unique low-grade malignancy with a low growth rate and both clinically and histopathologically distinct anamnesis beside the typical chondrosarcomas. [4]
Soft-tissue sarcomas commonly originate in the upper body, in the shoulder or upper chest. Some symptoms are uneven posture, pain in the trapezius muscle, and cervical inflexibility [difficulty in turning the head]. [12] The most common site to which soft-tissue sarcoma spreads is the lungs. [13]
A chondrosarcoma is the type of bone cancer that starts in the cartilage cells. It is the most common type found in adults. Unlike the other types it is rarely found in those under the age of twenty. Most chondrosarcomas develop in the pelvis, legs or arms. Benign counterparts are known as enchondromas. Chondrosarcomas are classified by grade ...
Myxoid chondrosarcoma is a type of chondrosarcoma. [1] It has been associated with a t(9;22) (q22;q12) EWS/CHN gene fusion. [2] References
“Just a few years ago, the average survival for stage III lung cancer — [two-thirds] of the study population — was 1.5 years. Now, in the era of immunotherapy, this number has been ...
A dislocated shoulder can be treated with: arthroscopic repairs; repair of the glenoid labrum (anterior or posterior) [1] In some cases, arthroscopic surgery is not enough to fix the injured shoulder. When the shoulder dislocates too many times and is worn down, the ball and socket are not lined up correctly.
Despite the success of chemotherapy for osteosarcoma, it has one of the lowest survival rates for pediatric cancer. The best reported 10-year survival rate is 92%; the protocol used is an aggressive intra-arterial regimen that individualizes therapy based on arteriographic response. [28]